ChulaCov19 mRNA vaccine Uses, Dosage, Side Effects and more

The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US. Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies. The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.

Trade Name ChulaCov19 mRNA vaccine
Generic ChulaCov19 mRNA vaccine
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share